Movement Disorder Program Awarded Novel NIH Clinical Research Grant to Study Rare Neurodegenerative Disease.

Dr. Irene Litvan, Raymond Lee Lebby Professor of Neurology and Director of the Movement Disorder Program has been awarded a $3.4 million NIH grant to study the genetic and environmental risk factors for progressive supranuclear palsy.


Effects of Coenzyme Q10 in Progressive Supranuclear Palsy:  A Multicenter, Randomized, Placebo-Controlled, Double Blind Study.  Principal Investigator:  Diana Apetauerova, MD
(ClinicalTrials.gov identifier:  NCT00382824)

This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).  The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD).  Currently, no effective treatment exists.  Coenzyme in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP.

Location & Contact Information
Lahey Clinic
Burlington, MA 01805
www.lahey.org

Stephanie A. Scala, MA
781-744-2950
Stephanie.A.Scala@lahey.org

Sharon G. Lamont, BS
781-744-5601
Sharon.G. Lamont@lahey.org

For more detailed information, visit www.clinicaltrials.gov